Spots Global Cancer Trial Database for Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury

Official Title: Effect of DPP4 Inhibitors on Cisplatin-induced Acute Kidney Injury

Study ID: NCT02250872

Conditions

Cancer

Cisplatin Adverse Reaction

Interventions

Gemigliptin

Placebo

Cisplatin

Study Description

Brief Summary: Cisplatin is a potent chemotherapeutic agent, however, its nephrotoxicity manifested by acute kidney injury (AKI) often limits applicability. Dipeptidylpeptidase-4 (DPP4) inhibitors are well known to improve glucose intolerance by augmentation of endogenous glucagon like peptide (GLP-1) and glucose-dependent insulinotropic peptide (GIP). DPP4 inhibitor also has the potential anti-apoptotic and renoprotective effect in a mouse model of cisplatin-induced AKI. This is a single-center, randomized, double-blind, parallel-group, placebo-controlled, prospective study to investigate the renoprotective effect of DPP4 inhibitor on cisplatin-induced AKI. A total 182 patients, who are scheduled to treat with cisplatin, will be recruited and randomly assigned to either Gemigliptin or placebo groups. Subjects will take study drugs for 8 days starting from one day before cisplatin treatment. Serum creatinine (Cr) and estimated glomerular filtration rate (eGFR) will be measured at 7 days after cisplatin treatment.

Detailed Description: This study will investigate possible renoprotective effects of DPP4 inhibitor on cisplatin induced acute kidney injury.